QQ客服 官方微博 反馈留言

浏览/检索结果: 共12条，第1-10条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity 期刊论文 JOURNAL OF CONTROLLED RELEASE, 2021, 卷号: 329, 页码: 1249-1261 作者:  Zhao, Pengfei;  Zhang, Jiaxin;  Wu, Aihua;  Zhang, Meng;  Zhao, Yuge 收藏  |  浏览/下载：109/0  |  提交时间：2021/05/24 Brain targeting delivery  Tumor-associated macrophage  Osimertinib resistance  Brain metastasis  Innate immunity  Combination therapy   Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins 期刊论文 DRUG METABOLISM AND PHARMACOKINETICS, 2020, 卷号: 35, 期号: 5, 页码: 456-465 作者:  Liu, Xiaoyun;  Feng, Dan;  Zheng, Mingyue;  Cui, Yongmei;  Zhong, Dafang 收藏  |  浏览/下载：13/0  |  提交时间：2020/12/21 Covalent tyrosine kinase inhibitors  Covalent binding  Human serum albumin  Molecular docking  Quantitative calculations  Linear modeling  Species difference   Simultaneous determination of sutetinib and its active metabolite sutetinibN-oxide in human plasma by liquid chromatography-tandem mass spectrometry: Evaluation of plasma stability 期刊论文 BIOMEDICAL CHROMATOGRAPHY, 2020, 页码: 9 作者:  Qiu, Yanan;  Tang, Chongzhuang;  Li, Ranran;  Cao, Sumin;  Zhang, Yuqiang 收藏  |  浏览/下载：30/0  |  提交时间：2020/12/24 LC-MS  MS  N-oxide  stability  sutetinib   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong 收藏  |  浏览/下载：39/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant 期刊论文 CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287 作者:  Hu, Xianglong;  Xun, Qiuju;  Zhang, Tao;  Zhu, Su-Jie;  Li, Qian 收藏  |  浏览/下载：47/0  |  提交时间：2020/07/01 EGFR(C797S) mutant  SARs  2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine  Clinical resistance  Fourth-generation inhibitors   Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11 作者:  Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan 收藏  |  浏览/下载：76/0  |  提交时间：2020/07/01 alflutinib  AST5902  metabolism  enzyme induction  drug-drug interaction   Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6 作者:  Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu 收藏  |  浏览/下载：14/0  |  提交时间：2020/07/01 LC-MS/MS  Alflutinib  AST2818  Pharmacokinetics  Human plasma   SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun 收藏  |  浏览/下载：22/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S)) 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 15, 页码: 7302-7308 作者:  Shen, Jiayi;  Zhang, Tao;  Zhu, Su-Jie;  Sun, Min;  Tong, Linjiang 收藏  |  浏览/下载：30/0  |  提交时间：2020/07/01